{"nctId":"NCT00514904","briefTitle":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects","startDateStruct":{"date":"2007-09-18","type":"ACTUAL"},"conditions":["Infections, Meningococcal","Meningococcal Vaccines"],"count":1504,"armGroups":[{"label":"Nimenrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Nimenrix"]},{"label":"Mencevax ACWY Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Mencevax"]}],"interventions":[{"name":"Nimenrix","otherNames":["Meningococcal vaccine GSK134612"]},{"name":"Mencevax","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents or guardians can and will comply with the requirements of the protocol.\n* A male or female between, and including, 2 and 10 years of age at the time of vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n* Previously completed routine childhood vaccinations to the best of his/her parents'/guardians' knowledge.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine.\n* Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W-135 and/or Y (for subjects below 6 years) or within the last five previous years (for subjects 6 years old or above).\n* Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroups A, C, W-135 and/or Y.\n* Previous vaccination with tetanus toxoid within the last month.\n* History of meningococcal disease.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination..\n* History of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s).\n* Major congenital defects or serious chronic illness.\n* Acute disease at the time of enrolment.\n* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Vaccine Response to N. Meningitidis Serogroups A (MenA), MenC, MenY and MenW-135","description":"Vaccine response was defined as an rSBA titer of at least 1:32 in subjects initially seronegative (\\< 1:8) and as 4-fold increase in titer from pre- to post-vaccination in subjects initially seropositive (≥ 1:8).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"529","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"664","spread":null},{"groupId":"OG001","value":"210","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"673","spread":null},{"groupId":"OG001","value":"195","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"670","spread":null},{"groupId":"OG001","value":"165","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Grade 3 General Symptoms (Solicited and Unsolicited)","description":"Grade 3 symptom was defined as symptom that prevented normal, everyday activities.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Titers Greater Than or Equal (≥) to the Cut-off Values","description":"The cut-off values for the rSBA titers were ≥ 1:8 and ≥ 1:128 respectively.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"491","spread":null},{"groupId":"OG001","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"739","spread":null},{"groupId":"OG001","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"476","spread":null},{"groupId":"OG001","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"739","spread":null},{"groupId":"OG001","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"224","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"738","spread":null},{"groupId":"OG001","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"736","spread":null},{"groupId":"OG001","value":"234","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"455","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"742","spread":null},{"groupId":"OG001","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"742","spread":null},{"groupId":"OG001","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"630","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"742","spread":null},{"groupId":"OG001","value":"248","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"590","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"742","spread":null},{"groupId":"OG001","value":"246","spread":null}]}]}]},{"type":"SECONDARY","title":"rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers","description":"Antibody titers were expressed as geometric mean titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219.1","spread":null},{"groupId":"OG001","value":"227.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6343.3","spread":null},{"groupId":"OG001","value":"2283.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"14.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4813.1","spread":null},{"groupId":"OG001","value":"1317","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.1","spread":null},{"groupId":"OG001","value":"68.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11543.2","spread":null},{"groupId":"OG001","value":"2157.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":null},{"groupId":"OG001","value":"241.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10825.1","spread":null},{"groupId":"OG001","value":"2613.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-tetanus Toxoid (Anti-TT) Concentrations Greater Than or Equal to (≥) the Cut-off Values","description":"The cut-off values for anti-TT concentrations were ≥ 0.1 international units per milliliter (IU/mL) and ≥ 1.0 IU/mL respectively.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"635","spread":null},{"groupId":"OG001","value":"220","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"733","spread":null},{"groupId":"OG001","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"296","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"720","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations","description":"Antibody concentrations were expressed as geometric mean concentrations (GMCs)","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null},{"groupId":"OG001","value":"0.744","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.731","spread":null},{"groupId":"OG001","value":"0.709","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polysaccharide (Anti-PS) Concentrations Greater Than or Equal to (≥) the Cut-off Values","description":"The cut-off values for anti-PS concentrations were ≥ 0.3 microgram per milliliter (μg/mL) and ≥ 2.0 μg/mL respectively for the anti- PSA, anti-PSC, anti-PSW-135 and anti-PSY antibodies respectively. One half of the subjects (50%, randomized) of the ATP cohort for immunogenicity was tested for anti-PSA and anti-PSC and the other half for anti-PSW-135 and anti-PSY.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"369","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"365","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"363","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"353","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"369","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"362","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polysaccharide (Anti-PS) Antibody Concentrations","description":"Anti-PS concentrations were expressed as geometric mean concentrations (GMCs) and expressed in μg/mL. One half of the subjects (50%, randomized) of the ATP cohort for immunogenicity was tested for anti-PSA and anti-PSC and the other half for anti-PSW-135 and anti-PSY.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null},{"groupId":"OG001","value":"25.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":null},{"groupId":"OG001","value":"0.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.61","spread":null},{"groupId":"OG001","value":"25.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"13.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.26","spread":null},{"groupId":"OG001","value":"22.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Less Than (<) 6 Years of Age With Solicited Local Symptoms","description":"Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom regardless of intensity grade.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects ≥ 6 Years of Age With Solicited Local Symptoms","description":"Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom regardless of intensity grade.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects < 6 Years of Age With Solicited General Symptoms","description":"Solicited general symptoms assessed were drowsiness, fever (measured orally and temperature ≥ 37.5°C ), irritability and loss of appetite. Any was defined as incidence of any general symptom regardless of intensity grade or relationship to vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects ≥ 6 Years of Age With Solicited General Symptoms","description":"Solicited general symptoms assessed were fatigue, fever (measured orally and temperature ≥ 37.5°C ), gastrointestinal and headache. Any was defined as incidence of any general symptom regardless of intensity grade or relationship to vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Specific Adverse Events (AEs)","description":"Specific AEs include: rash; new onset of chronic illness(es) (NOCI) and/ or conditions prompting emergency room (ER) visits or non-routine physician office visits.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Unsolicited Symptoms","description":"Unsolicited symptom covers any symptom reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability /incapacity or are a congenital anomaly/ birth defect in the offspring of a study subject.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":1125},"commonTop":["Pain (≥ 6 years of age)","Pain (< 6 years of age)","Redness (≥ 6 years of age)","Redness (< 6 years of age)","Swelling (≥ 6 years of age)"]}}}